NCT03763162 2026-04-15Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaM.D. Anderson Cancer CenterPhase 2 Active not recruiting40 enrolled